Fig. 1From: Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVsThe schematic diagram showed a bioreactive fibrin gel containing PexD biomimetic nanoparticles and aPD-L1 sprayed in situ in the tumour bed after surgery. Combining chemotherapy and immunotherapy to eliminate residual in situ tumour cells and capture circulating tumour cells prevents melanoma recurrence and metastasisBack to article page